ArticleBreast care (Basel, Switzerland)2024

Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.

Thomas Decker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.